重组抗小鼠CTLA-4单抗(9D9) | Syd Labs PA007380.m2aLA
重组抗小鼠CTLA-4单抗(克隆号9D9) ，小鼠IgG2a-LALAPG Kappa，体内实验级 (货号：PA007380.m2aLA）是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究。Syd Labs PA007380.m2aLA抗小鼠CTLA-4抗体不变区为小鼠IgG2a-LALAPG Kappa，可与重组小鼠IgG2a-LALAPG同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007380.m2aLA |
|---|---|
| 产品名称 | 重组抗小鼠CTLA-4单抗(9D9) | Syd Labs PA007380.m2aLA |
| 英文名 | In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 细胞毒性T淋巴细胞相关抗原4，细胞毒性T细胞抗原4，CD152，CTLA4 |
| 概述 | Syd Labs提供重组小鼠IgG2a-LALAPG同型对照抗体，样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 9D9 |
| 同种型 | 小鼠 IgG2a, kappa |
| 应用 | ELISA、流式细胞术（flow cytometry）、中和（neutralization）、功能测定（functional assays），如生物分析PK和ADA测定，以及用于研究受小鼠CTLA-4蛋白影响的生物途径的测定。 |
| 免疫源 | 抗小鼠CTLA-4单克隆抗体（克隆：9D9）在哺乳动物细胞中产生。 |
| 抗体形式 | 0.2 μM过滤溶液，pH 7.4，不含稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CTLA-4单克隆抗体，小鼠IgG2a-LALAPG Kappa(克隆号9D9)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存1个月。 如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007380.m2cLA Syd Labs提供重组小鼠IgG2a-LALAPG同型对照抗体，样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术（flow cytometry）、中和（neutralization）、功能测定（functional assays），如生物分析PK和ADA测定，以及用于研究受小鼠CTLA-4蛋白影响的生物途径的测定。 |
文献
PA007380.m2aLA: Syd Labs体内实验级重组抗小鼠CTLA-4单克隆抗体（克隆号9D9），小鼠IgG2a-L234A L235A P329G (LALAPG) Kappa（In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)）
9D9 抗体可阻断小鼠细胞毒性 T 淋巴细胞抗原-4（CTLA-4）。阻断 CTLA-4 可以消除减弱 T 淋巴细胞活性的抑制性信号。细胞毒性 T 淋巴细胞抗原-4（CTLA-4）是一种抑制性分子，它与刺激性分子 CD28 竞争结合抗原呈递细胞上的 B7。CTLA-4 和 CD28 均表达于 T 细胞表面。
抗小鼠 CTLA-4 单克隆抗体（克隆号：9D9）参考文献：
Darren J Schofield, et al. MAbs. 2021 Jan-Dec;13(1):1881267. PMID: 33397194; PMCID: PMC7831362
“Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1, and CTLA-4 may not demonstrate cross-reactive binding to their mouse orthologs, and surrogate anti-mouse antibodies are often used in their place to inhibit these immune checkpoints. To develop relevant murine surrogate antibodies for the anti-human PD-L1 mAb durvalumab and the anti-human CTLA-4 mAb tremelimumab, rat/mouse chimeric or fully murine mAbs engineered for reduced effector function were developed and compared with durvalumab and tremelimumab.”
2. Leukemic B Cell CTLA-4 Suppresses Co-stimulation of T cells
Priscilla Do, et al. J Immunol. 2019 May 1;202(9):2806-2816. PMID: 30910862; PMCID: PMC6478536
“The clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive role for tumor-expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease model. Coculture with activated human T cells induced surface CTLA-4 on primary human CLL B cells.”
3. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du, et al. Cell Res. 2018 Apr;28(4):416-432. PMID: 29472691; PMCID: PMC5939050
“It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Consequently, Ipilimumab does not increase B7 on dendritic cells (DCs) from either CTLA4 gene humanized or human CD34+ stem cell-reconstituted NSG? mice.”
Timothy Affolter, et al. PLoS One. 2019 May 21;14(5):e0217276. PMID: 31112568; PMCID: PMC6528985
“Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase 1 (IDO1) to evade immune control. Checkpoint inhibitors have demonstrated durable anti-tumor efficacy in human and preclinical models. Liver toxicity is one of the common immune-related adverse events associated with checkpoint inhibitors (CPIs) and its frequency and severity often increase significantly during CPI combination therapies.”
Anne M?nsson Kvarnhammar, et al. J Immunother Cancer. 2019 Apr 11;7(1):103. PMID: 30975201; PMCID: PMC6458634
“The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current treatment regimens may limit their use. Thus, there is a medical need for new CTLA-4 targeting therapies with improved benefit-risk profile.”
了解更多抗小鼠CTLA-4单克隆抗体（clone：9D9）参考文献，请查看：抗小鼠CTLA-4抗体（克隆号9D9）参考文献
Syd Labs抗小鼠CTLA-4重组抗体（克隆号9D9），小鼠IgG2a-LALAPG Kappa（货号：PA007380.m2aLA）推荐同型对照抗体: